RecruitingNot ApplicableNCT06329037

The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

Sponsor

University of Electronic Science and Technology of China

Enrollment

80 participants

Start Date

Mar 5, 2024

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria2

Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
Normal or corrected-normal version

Exclusion Criteria12

History of neuropsychiatric diseases.
History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
History of renal diseases, including renal stones or renal failure.
History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
Infections such as COVID-19 or influenza, or unexplained fever.
Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
Blood donation (≤ 1 month prior to administration).
Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
Pregnant or breastfeeding.